Literature DB >> 29536006

Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis.

Reinier Snetselaar1, Matthijs F M van Oosterhout2, Jan C Grutters1,3, Coline H M van Moorsel1,3.   

Abstract

The enzyme telomerase reverse transcriptase (TERT) is essential for telomere maintenance. In replicating cells, maintenance of telomere length is important for the preservation of vital genetic information and prevention of genomic instability. A common genetic variant in TERT, rs2736100 C/A, is associated with both telomere length and multiple diseases. Carriage of the C allele is associated with longer telomere length, while carriage of the A allele is associated with shorter telomere length. Furthermore, some diseases have a positive association with the C and some with the A allele. In this study, meta-analyses were performed for two groups of diseases, cancerous diseases, e.g., lung cancer and non-cancerous diseases, e.g., pulmonary fibrosis, using data from genome-wide association studies and case-control studies. In the meta-analysis it was found that cancer positively associated with the C allele (pooled OR 1.16 [95% CI 1.09-1.23]) and non-cancerous diseases negatively associated with the C allele (pooled OR 0.81 [95% CI 0.65-0.99]). This observation illustrates that the ambiguous role of telomere maintenance in disease hinges, at least in part, on a single locus in telomerase genes. The dual role of this single nucleotide polymorphism also emphasizes that therapeutic agents aimed at influencing telomere maintenance should be used with caution.

Entities:  

Keywords:  cancer; degenerative disease; single nucleotide polymorphism; telomerase; telomere

Year:  2018        PMID: 29536006      PMCID: PMC5835035          DOI: 10.3389/fmed.2018.00041

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


Introduction

Telomere biology is emerging as a significant factor in an increasing number of diseases (1–4). Studies have found disease associations with both abnormal telomere length and with genetic variants are related to telomere biology (5–7). Telomeres are non-coding tandem repeats spatially organized by specialized proteins that maintain stability of the chromosome ends (8–10). Furthermore, telomeres serve as a buffer against the shortening of chromosomes, thereby preventing the loss of vital genetic information (11). To maintain replicative potential, telomeres can be elongated by the ribonucleoprotein telomerase (12, 13). Telomerase consists of a catalytic protein component, encoded by the gene telomerase reverse transcriptase (TERT), and a RNA template, encoded by telomerase RNA component. Over the course of the human lifespan, the average length of telomeres can be disproportionally influenced by a number of factors, leading to a broad spectrum of diseases. Genetic variation in telomere maintenance genes has been shown to either accelerate or prohibit telomere shortening. Genomic mutations in the coding regions of telomerase genes are primarily found in degenerative diseases like dyskeratosis congenita, aplastic anemia, and idiopathic pulmonary fibrosis (IPF) (14–16). These mutations generally lead to a decrease in telomerase activity (17) and shorter telomeres in mutation carriers who develop fatal disease due to organ failure. Mutations in the coding regions of telomerase genes are very rare in cancer, however, somatic mutations in the promotor region of the TERT gene has been reported in the context of several cancer types (18–20). These mutations generally lead to an increase in telomerase activity, which corroborates the observation of high levels of telomerase activity in cancer cells (21). Telomerase activation and the subsequent telomere elongation lead to the immortalization of cells and prevent fatal instability of the chromosomes, opening up the possibility of unrestricted cell proliferation (21, 22). However, Telomere biology is an ambiguous factor in cancer pathology (23–25). In healthy individuals it is thought that the restricted transcription of telomerase and the resulting limited number of cell divisions present a barrier to unlimited replication of somatic cells, thus preventing cancer (26, 27). However, other research suggests that telomere shortening can lead to chromosomal instability in the form of chromosome fusion, genomic copy addition, deletion, and mutation, which in turn can lead to tumor initiation (22, 28–31). This duplicity is apparent in humans, where both long and short telomere length of white blood cells has been associated with different cancers (32–36). As short telomeres can lead to damaged chromosomes, it is proposed that long telomeres postpone senescence, thereby increasing the risk for cells to acquire genetic abnormalities that facilitate tumorigenesis (35, 37, 38). Besides rare mutations in telomerase genes, common genetic variation in these genes has also been associated with disease. A well-studied example is the single nucleotide polymorphism (SNP) rs2736100 in the TERT gene (5p15.33). Interestingly, the first report on a disease association to this SNP, was to the non-cancerous disease IPF (39). An IPF susceptibility odds ratio (OR) of 1.82 [95% CI: 1.47–2.22] was found for the A allele of this SNP. The second report on this SNP showed an association between lung cancer and the C allele of this SNP (40). Later studies have shown an association between the A allele and shorter blood cell telomere length, while it follows that the C allele is associated with longer telomeres (41, 42). This duality in disease association of the rs2736100 alleles might reflect a fundamentally different role of telomere biology in cancerous diseases as opposed to non-cancerous diseases. Such a dichotomy would underline that therapeutic agents influencing telomere length or telomerase activity should be used with caution, as both (too) long and short telomeres could lead to disease. The aim of this study is to conduct a systematic review and meta-analysis of disease association studies with TERT SNP rs2736100 and to gain insight in the balancing act between telomere maintenance and disease predisposition.

Materials and Methods

Study Selection

The electronic databases PubMed and Embase were queried for studies on TERT SNP rs2736100 by using “rs2736100” as search input (Figure 1). Initially 92 studies were found. After selecting for papers pertaining to the subject of these review 57 studies remained. Of these, 49 studies described associations between TERT SNP rs2736100 and cancer, and 8 studies described associations between this SNP and non-cancer disease. Another 28 studies were added through references found in the original studies. Excluded were reviews and meta-analyses, and studies from which no OR data was available or could be calculated. Furthermore, studies were excluded that did not provide definite data on which allele was associated with risk for the investigated disease. Finally, 85 studies were included of which 77 described association with cancer and 8 with non-cancer and the TERT SNP, respectively.
Figure 1

Flowchart of studies included in the meta-analysis.

Flowchart of studies included in the meta-analysis.

Eligibility Criteria

Included in this meta-analysis were case-control and genome-wide association studies assessing the association between TERT SNP rs2736100 and disease. These studies were furthermore included when the associated allele and the used inheritance model were clearly derivable from the study. Results of meta-analyses were excluded; however, these studies were searched for eligible studies to be included in the present study. This lead to further inclusion of studies that did not find significant associations between rs2736100 and disease, thereby preventing major publication bias. Finally, systematic reviews, abstracts, non-english studies and studies investigating rs2736100 not in the context of disease were excluded from the meta-analysis.

Data Extraction

The following data was derived from each study: first author, year of publication, number of cases and controls, associated disease (cancer and non-cancer), and OR and 95% confidence interval (95% CI). Furthermore, the used inheritance model was checked as well as in which allele specifically was associated with the studied disease. When this information was not provided it was derived from the provided genotype data when possible.

Bias Evaluation

(Publication) bias was evaluated by visual inspection of Doi plots, as well as calculates the Luis Furuya-Kanamori (LFK) index, which provides a statistic for the amount of bias in a Doi plot (No asymmetry: LFK index within ±1, minor asymmetry: LFK index exceeds ±1 but within ±2, major asymmetry: LFK index exceeds ±2).

Statistical Analysis

rs2736100 associations and (publication) bias were both analyzed using meta-analysis software MetaXL 4.0 (EpiGear International, Sunrise Beach, Australia). Due to the large number of different diseases that were included in this study, a high level of variation in study outcome, heterogeneity, was expected. The meta-analysis was, therefore, performed using the inverse variance heterogeneity method, to determine the pooled result and heterogeneity (43). Many studies do not provide genotype data. Therefore, we performed meta-analysis on the OR and 95% CI for allelic association.

Results

Non-Cancerous Diseases

A meta-analysis was performed to analyze the association of TERT SNP rs2736100 with a group of cancer diseases and with a group of non-cancerous diseases. Table 1 shows all included studies. For the non-cancer group, 8 studies were found with diagnoses of pulmonary fibrosis and coronary heart disease among others. Each of these eight studies showed either a negative association between the C allele and disease or a non-significant result. Figure 2 shows a forest plot of a meta-analysis of these studies using the inverse variance heterogeneity model (43). The OR in this figure is an effect measure for the association with the C allele of rs2736100 in a co-dominant model. The pooled negative association with disease for the C allele was significant with an OR ratio of 0.81 [95% CI: 0.65–0.99]. Presence of the C allele is protective for non-cancerous diseases.
Table 1

Studies included in the meta-analyses.

Association rs2736100_C
StudyCasesControlsOdds ratio95% CIDisease
(44)2454891.120.90–1.39Pediatric brain tumor
(45)4454971.291.07–1.55Lung cancer
(46)1,1541,1371.241.10–1.39Lung cancer
(47)1,8961,9391.131.03–1.24Pancreatic cancer
(48)1,0941,1001.141.01–1.30Lung cancer
(49)4,4415,1941.221.15–1.29Lung cancer
(50)5,5507,5850.910.99–0.84Pancreatic cancer
(51)9761,0571.261.11–1.43Glioma
(52)1962291.651.17–2.32Lung cancer
(53)13,26540,2451.081.12–1.04Endometrial cancer
(54)2432461.200.92–1.55Gastric cancer
(55)3865870.940.78–1.14Liver cancer
(41)22,23364,7620.770.50–1.17Coronary artery disease
(56)6634200.990.79–1.25Renal cell carcinoma
(57)8451,1901.271.12–1.44Glioma
(58)1,5142,4701.010.92–1.10Coronary artery disease
(59)1,1361,0121.020.90–1.15Gastric cancer
(60)6396491.371.18–1.61Glioma
(61)3,1313,7021.020.94–1.11Skin cancer
(62)842571.150.81–1.63Arteriosclerosis
(63)2,4776,5500.730.68–0.78Pulmonary fibrosis
(64)9705251.171.04–1.33Bladder cancer
(65)5109131.171.00–1.37Skin cancer
(66)3,2641,7930.980.77–1.25Colorectal cancer
(67)2,3082,3211.481.36–1.62Lung cancer
(68)8,5599,3781.251.20–1.31Lung cancer
(69)1,1451,1420.960.78–1.17Breast cancer
(70)7167161.171.00–1.38Lung cancer
(71)7172021.571.25–1.96Myeloproliferative neoplasms
(72)1041351.010.70–1.46Colorectal cancer
(73)8558441.161.02–1.33Lung cancer
(74)1,2121,3391.141.02–2.27Lung cancer
(75)3499140.810.68–0.97Testicular cancer
(76)16,03916,4300.930.91–0.96Colorectal cancer
(77)3701,1731.381.23–1.56Lung cancer
(78)5844001.771.47–2.12Myeloproliferative neoplasms
(79)5181,2011.641.42–1.91Glioma
(80)8551,1601.161.01–1.33Glioma
(81)4,5435,5051.381.31–1.47Lung cancer
(82)1931971.291.00–1.67Lung cancer
(83)5,7395,8481.091.03–1.15Lung cancer
(84)3701,2631.100.93–1.29Colorectal cancer
(85)2,2832,7851.181.09–1.27Lung cancer
(86)3043191.331.06–1.67Lung cancer
(87)6901,5381.191.03–1.38Bladder cancer
(88)5,4574,4931.381.30–1.47Lung cancer
(40)5,8709,3191.141.08–1.20Lung cancer
(89)2,08611,0341.271.19–1.37Lung cancer
(90)2268061.220.99–1.51Acute myeloid leukemia
(91)2268061.441.10–1.88Glioma
(39)2421,4960.550.45–0.68Idiopathic pulmonary fibrosis
(92)3524471.180.97–1.45Lung cancer
(34)2778311.191.04–1.37Skin cancer
(93)1,6811,6351.161.04–1.30Lung cancer
(94)3,5344,0981.081.02–1.16Breast cancer
(95)1,9551,9951.111.00–1.23Pancreatic cancer
(96)5961,4801.080.94–1.23Endometrial cancer
(97)1,8544,9491.301.19–1.41Glioma
(98)8103,0801.231.10–1.37Glioma
(99)1,0291,6681.311.17–1.47Glioma
(100)6605230.920.78–1.09Breast cancer
(100)3723630.950.77–1.16Prostate cancer
(101)5696561.231.05–1.45Acute lymphoblastic leukemia
(102)1,8783,6701.271.19–1.37Glioma
(103)5,99213,5311.341.28–1.41Lung cancer
(104)8077081.241.05–1.48Lung cancer
(105)8104,4791.311.16–1.48Myeloproliferative neoplasms
(106)7196,0301.080.97–1.21Lung cancer
(107)10,81213,9131.151.10–1.20Lung cancer
(108)6611,3471.321.14–1.52Lung cancer
(109)1,0458,4030.750.67–0.85Testicular cancer
(110)1,6601,2991.391.28–1.50Glioma
(111)1,6187,7361.391.28–1.50Glioma
(112)2395531.301.04–1.61Lung cancer
(113)1,0331,0531.161.03–1.32Cervical cancer
(114)1,5521,6051.201.09–1.33Lung cancer
(115)3706860.780.63–0.96Interstitial lung disease
(116)1,4045,0401.241.10–1.39Lung cancer
(117)2391,1970.890.73–1.08Depression
(118)6923,9921.511.35–1.71Glioma
(119)5805800.810.69–0.95Male infertility
(120)1,7351,0361.110.99–1.24Lung cancer
(121)5245241.341.13–1.60Lung cancer
(122)1,4253,0111.261.11–1.43Lung cancer
(123)7847821.281.11–1.47Lung cancer
(124)2,0962,1471.381.27–1.51Esophageal cancer
Figure 2

Meta-analysis of non-cancer association to rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.

Studies included in the meta-analyses. Meta-analysis of non-cancer association to rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.

Association with Cancer

Meta-analysis for associations with cancer included 77 studies. These studies included a variety of cancers of which the majority (n = 46) involved studies on lung cancer (n = 33) and glioma (n = 13). The majority of studies reported a positive association with the C allele of rs2736100. However, four of the included studies reported a negative association with the C allele, these included two studies on testicular cancer, one on colorectal cancer and one on pancreatic cancer (50, 76, 109). In the meta-analysis of cancer studies, the pooled effect size was significant with a pooled OR of 1.16 [95% CI: 1.09–1.23] (Figure 3) and shows that the C allele is a risk allele for cancer.
Figure 3

Meta-analysis of cancer association to rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.

Meta-analysis of cancer association to rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval. Figure 4 shows the significant pooled ORs for the meta-analysis of cancer and non-cancer diseases.
Figure 4

Overall association of the cancer and age-related group of diseases with telomerase reverse transcriptase rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval.

Overall association of the cancer and age-related group of diseases with telomerase reverse transcriptase rs2736100 allele C. OR, odds ratio; 95% CI, 95% confidence interval. Potential bias from publication selection and other sources was evaluated using Doi plots and quantified by the LFK index (Figure 5). Figure 5A shows the Doi plot for the cancer meta-analysis. A LFK index of 109 was found from indication minor influence from publication bias or bias from other sources. Figure 5B shows the Doi plot for non-cancer diseases.
Figure 5

Evaluation of (publication) bias for the cancer (A) and non-cancer (B) meta-analysis. LFK index, Luis Furuya-Kanamori index; OR, odds ratio.

Evaluation of (publication) bias for the cancer (A) and non-cancer (B) meta-analysis. LFK index, Luis Furuya-Kanamori index; OR, odds ratio.

Discussion

The results of the meta-analyses illustrate the duality of telomere biology in disease predisposition. Pooled analysis showed that non-cancerous diseases, such as pulmonary fibrosis and coronary artery disease, associate positively with the telomerase A allele that is linked to shorter telomeres. Pooled analysis of cancer studies, however, showed an association with the opposite allele, the C allele that is linked to longer telomere length. This is supported by a recent study that showed an association of genetically increased telomere length and cancer, while the opposite protected against non-cancerous diseases (125). This two-sided association suggests opposite roles of telomere length in cancerous and non-cancerous diseases. The TERT SNP rs2736100 has robustly been associated with telomere length in healthy controls (41, 42). Studies showed that presence of the A allele is associated with shorter telomere length. This is in congruence with observations made in IPF, cardiovascular disease, and male infertility, where patients have been shown to have relatively short leukocyte telomeres (126–128). This SNP could, therefore, be part of the genetic background that increases susceptibility to these diseases in combination with other cellular and environmental factors that might cause increased cellular turnover (129). On the other hand, the C allele, which is associated with most cancer types, is associated with longer telomere length in health (42, 101). How the rs2736100 SNP influences telomere length is presently not understood. The SNP is located in intron 2 in TERT and was suggested to influence telomerase activity or to be in strong linkage with a functional variant in TERT (83, 101). The dual associations of the SNP in this study would support the hypothesis that telomere maintenance is at an intersection between cancer- and premature-aging (130, 131). Cancer and aging share many molecular pathways, including telomere maintenance pathways. And while aging is associated with a progressive decrease in telomere length, cancer is characterized by immortalization of the cell often through telomerase activation (21, 132). Short telomeres accelerate aging through cell senescence, but long telomeres postpone senescence, which in turn, facilitates survival of cells with acquired oncogenic DNA alterations and thereby promotes tumorigenesis (35, 37, 38). The meta-analysis of cancer studies showed a pooled positive correlation with the TERT allele that is known to cause longer telomeres. This suggests that the majority of patients develop cancer due to a.o. the presence of long telomeres in tumor initiating cells. On the other hand, it is also well understood that critically short telomeres lead to chromosomal instability, which can cause tumorigenesis (32, 33, 36). Although the results of the meta-analysis suggest this if not the cause in the majority of cases, four cancer studies were included that originally reported an association with the TERT allele for short telomeres. For colorectal cancer there is general agreement that short telomere length increases tumor initiation by causing chromosomal instability (133). This would account for the association of colorectal cancer with the A allele of rs2736100 that is also associated with short telomere length (76). Testicular cancer is also associated with the A allele (109). Telomerase activity is restricted in most tissues, one exception being germ cells (21). It is assumed that in highly proliferative tissues, a genetic factor decreasing telomerase activity may cause chromosomal instability leading to cancer. Most non-cancer diseases showed an association with the A allele of rs2736100 SNP. Regarding telomere biology, disease susceptibility for pulmonary fibrosis is opposite to that of lung cancer, while both diseases are highly associated with smoking behavior. In case of short telomeres, smoking may cause increased senescence with subsequent pulmonary fibrosis, while in case of long telomeres; smoking may cause DNA damage in cells with sustained proliferative capacity. For coronary artery disease no significant allelic association has been found for rs2736100. But reports have shown a significant effect of this variant when analyzed in combination with other risk loci or when analyzed in a dominant model (41, 58, 62). However, conflicting data were found for the direction of the association, which could have been due to the ethnic background of the population. Codd et al. reported an association between coronary artery disease and the A allele in a Caucasian cohort. Both Feng et al. and Ding et al. study Asian populations found no association or an association with the C allele (58, 62). A limitation is that although an exhaustive literature search was performed, studies could have been overlooked. Some studies were excluded because of missing genotype data and some described an association without reporting the associated allele. Furthermore, it should be emphasized that the pathogenesis for most of the diseases mentioned in this study is not fully known and is suggested to be complex, involving both genetic and environmental factors. Another limitation is the discrepancy in the number of studies found for cancer vs non-cancer. This results in a strong influence of interstitial lung disease on the pooled OR. Finally, (publication) bias was evaluated for both the cancer and non-cancer study (Figure 5). For both, meta-analyses asymmetry was minor and the corresponding bias introduced by study selection and other sources is, therefore, also considered to be of minor influence on the pooled result. The ambiguous effects of telomere maintenance do pose a great challenge for the development of therapeutic agents, for instance putative anti-aging therapeutics. Therapeutic agents aimed at increasing telomere length should be used with caution (25, 134). Telomerase activating agents used in the context of degenerative or aging-related diseases could facilitate tumorigenesis or lead to proliferation of untargeted tissues (131, 135). On the other hand, in relation to cancer, telomerase inhibiting agents are attractive candidates, but could lead to accelerated tissue degeneration or negatively affect stem cell function and immune response as this requires increased telomerase activity to sustain a high level of cell proliferation (135, 136). To develop disease-specific treatment, future research should be aimed at further understanding of optimal telomere length per specific tissues during life, and at the ability to target specific cell-types or tissues very accurately.

Conclusion

Meta-analyses showed that the TERT SNP rs2736100 C allele is positively associated with multiple cancerous diseases, while the A allele is positively associated with predisposition to non-cancerous (degenerative) diseases. Because the SNP is known for its influence on telomere length, this result illustrates that optimal telomere maintenance balances between increasing the risk for cancer or for non-cancerous diseases. This underlines the caution that should be taken when developing therapies that influence telomere length.

Author Contributions

RS and CM contributed to the study concept and design, data analysis and interpretation, writing of the manuscript and final approval; had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MO and JG contributed to the study concept and design, writing of the manuscript and final approval; had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  136 in total

1.  Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.

Authors:  Daiki Miki; Michiaki Kubo; Atsushi Takahashi; Kyong-Ah Yoon; Jeongseon Kim; Geon Kook Lee; Jae Ill Zo; Jin Soo Lee; Naoya Hosono; Takashi Morizono; Tatsuhiko Tsunoda; Naoyuki Kamatani; Kazuaki Chayama; Takashi Takahashi; Johji Inazawa; Yusuke Nakamura; Yataro Daigo
Journal:  Nat Genet       Date:  2010-09-26       Impact factor: 38.330

2.  The Stability of Broken Ends of Chromosomes in Zea Mays.

Authors:  B McClintock
Journal:  Genetics       Date:  1941-03       Impact factor: 4.562

3.  Telomere length and genetic analyses in population-based studies of endometrial cancer risk.

Authors:  Jennifer Prescott; Monica McGrath; I-Min Lee; Julie E Buring; Immaculata De Vivo
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

4.  Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk.

Authors:  Mahboobeh Safaeian; Preetha Rajaraman; Patricia Hartge; Meredith Yeager; Martha Linet; Mary Ann Butler; Avima M Ruder; Mark P Purdue; Ann Hsing; Laura Beane-Freeman; Jane A Hoppin; Demetrius Albanes; Stephanie J Weinstein; Peter D Inskip; Alina Brenner; Nathaniel Rothman; Nilanjan Chatterjee; Elizabeth M Gillanders; Stephen J Chanock; Sophia S Wang
Journal:  Cancer Causes Control       Date:  2013-08-01       Impact factor: 2.506

5.  Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma.

Authors:  Robert J Clifford; Jinghui Zhang; Daoud M Meerzaman; Myung-Soo Lyu; Ying Hu; Constance M Cultraro; Richard P Finney; Jenny M Kelley; Sol Efroni; Sharon I Greenblum; Cu V Nguyen; William L Rowe; Sweta Sharma; Gang Wu; Chunhua Yan; Hongen Zhang; Young-Hwa Chung; Jeong A Kim; Neung Hwa Park; Il Han Song; Kenneth H Buetow
Journal:  Hepatology       Date:  2010-12       Impact factor: 17.425

6.  Role of selected genetic variants in lung cancer risk in African Americans.

Authors:  Margaret R Spitz; Christopher I Amos; Susan Land; Xifeng Wu; Qiong Dong; Angela S Wenzlaff; Ann G Schwartz
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

Review 7.  Telomerase at the intersection of cancer and aging.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Trends Genet       Date:  2013-07-19       Impact factor: 11.639

8.  Significant association of 5p15.33 (TERT-CLPTM1L genes) with lung cancer in Chinese Han population.

Authors:  Zhenhong Zhao; Cong Li; Lixin Yang; Xiaobo Zhang; Xueying Zhao; Xiao Song; Xiaoying Li; Jiucun Wang; Ji Qian; Yajun Yang; Li Jin; Hongyan Chen; Daru Lu
Journal:  Exp Lung Res       Date:  2013-01-31       Impact factor: 2.459

9.  Association between previously identified loci affecting telomere length and coronary heart disease (CHD) in Han Chinese population.

Authors:  Hui Ding; Fen Yan; Lin-Lin Zhou; Xiu-Hai Ji; Xin-Nan Gu; Zhi-Wei Tang; Ru-Hua Chen
Journal:  Clin Interv Aging       Date:  2014-05-27       Impact factor: 4.458

10.  TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Authors:  M Labussière; A L Di Stefano; V Gleize; B Boisselier; M Giry; S Mangesius; A Bruno; R Paterra; Y Marie; A Rahimian; G Finocchiaro; R S Houlston; K Hoang-Xuan; A Idbaih; J-Y Delattre; K Mokhtari; M Sanson
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

View more
  7 in total

1.  Association of Leukocyte Telomere Length and Genes Involved in its Regulation With Oral Carcinoma.

Authors:  Zaneta Jumatovaite; Albertas Kriauciunas; Alvita Vilkeviciute; Greta Gedvilaite; Vykintas Liutkevicius; Virgilijus Uloza; Alina Smalinskiene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  Trade-offs in aging lung diseases: a review on shared but opposite genetic risk variants in idiopathic pulmonary fibrosis, lung cancer and chronic obstructive pulmonary disease.

Authors:  Coline H M van Moorsel
Journal:  Curr Opin Pulm Med       Date:  2018-05       Impact factor: 3.155

3.  Systematic meta-analyses, field synopsis and global assessment of the evidence of genetic association studies in colorectal cancer.

Authors:  Zahra Montazeri; Xue Li; Christine Nyiraneza; Xiangyu Ma; Maria Timofeeva; Victoria Svinti; Xiangrui Meng; Yazhou He; Yacong Bo; Samuel Morgan; Sergi Castellví-Bel; Clara Ruiz-Ponte; Ceres Fernández-Rozadilla; Ángel Carracedo; Antoni Castells; Timothy Bishop; Daniel Buchanan; Mark A Jenkins; Temitope O Keku; Annika Lindblom; Fränzel J B van Duijnhoven; Anna Wu; Susan M Farrington; Malcolm G Dunlop; Harry Campbell; Evropi Theodoratou; Wei Zheng; Julian Little
Journal:  Gut       Date:  2019-12-09       Impact factor: 23.059

Review 4.  Scar tissue to lung cancer; pathways and treatment.

Authors:  Konstantinos Sapalidis; Chrysanthi Sardeli; Efstathios Pavlidis; Georgios Koimtzis; Charilaos Koulouris; Nikolaos Michalopoulos; Stylianos Mantalovas; Theodora Tsiouda; Ioannis Passos; Christoforos Kosmidis; Dimitrios Giannakidis; Valeriu Surlin; Athanasios Katsaounis; Vyron Alexandrou; Aikaterini Amaniti; Paul Zarogoulidis; Haidong Huang; Qiang Li; Stelian Mogoanta; Isaac Kesisoglou
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

Review 5.  TERT-Regulation and Roles in Cancer Formation.

Authors:  Marta Dratwa; Barbara Wysoczańska; Piotr Łacina; Tomasz Kubik; Katarzyna Bogunia-Kubik
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

6.  Do Polymorphisms of the TERT, GSTM1, and GSTT1 Genes Increase Laryngeal Cancer Susceptibility in Smokers of Romanian Descent?

Authors:  Corina Iulia Cornean; Andreea Catana; Alma Aurelia Maniu
Journal:  Medicina (Kaunas)       Date:  2022-08-16       Impact factor: 2.948

7.  Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.

Authors:  Matteo Giaccherini; Angelica Macauda; Nicola Sgherza; Juan Sainz; Federica Gemignani; Josè Manuel Sanchez Maldonado; Manuel Jurado; Francesca Tavano; Grzegorz Mazur; Andrés Jerez; Joanna Góra-Tybor; Aleksandra Gołos; Francisca Hernández Mohedo; Joaquin Martinez Lopez; Judit Várkonyi; Raffaele Spadano; Aleksandra Butrym; Federico Canzian; Daniele Campa
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.